Velocity Fund Partners, a Pittsburgh private equity company, has acquired the Philadelphia clinical contract research organization (CRO) Indipharm and is relaunching the CRO as InClinica. Financial terms were not disclosed. Velocity Fund Partners targets promising life sciences opportunities and believes InClinica is well-positioned for growth. “InClinica’s existing global footprint and experience in early drug and device development and clinical trials, combined with Velocity’s unique exp...